CRL Stock Analysis — Charles River Laboratories
Sector: Healthcare
AI Verdict
CRL trades at 16x next year's earnings—cheap for a specialized healthcare service if its client lock-in holds, but the lack of revenue growth means you're betting the moat will reignite topline momentum soon.
Competitive Moat
Charles River Laboratories provides preclinical research services to pharmaceutical and biotech companies, embedding itself early in the drug development pipeline. Its moat comes from deep client integration and regulatory expertise, making switching costly and risky for clients with sensitive R&D timelines.
Summary
CRL stands out for its entrenched relationships with drug developers who rely on its preclinical research services.
Where It Stands
The stock is up 27.98% over the past year, trades at 16.0x forward earnings versus the healthcare sector median of 22x, and its RSI of 45.5 signals cooling momentum.
Key Metrics
- RSI: 45.5 — Neutral
- Forward P/E: 16.0x
- Revenue Growth: -0.0%
- Market Cap: $8.8B
- 1-Year Return: 27.98%
- 52-Week High: $228.88
- 52-Week Low: $132.58
Analyst Consensus
15 Buy · 9 Hold · 0 Sell (24 analysts)
Bull Case
A forward P/E of 16.0x is a discount to the sector despite the company’s sticky client base and a 27.98% 1-year return.
Bear Case
Trailing revenue shrank -0.9% and if the P/E reverts to 14x (the financials median), the stock could lose another 12.5% from here.
Catalyst to Watch
Watch for a return to positive revenue growth in quarterly results, which would justify the current valuation premium over financials.